Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CUR102
- Development stage
- Preclinical
- Lead developer
- Curamys
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
CUR102 is a discovery-stage microRNA (miRNA) therapeutic being developed by Curamys for the treatment of Duchenne Muscular Dystrophy (DMD). The drug candidate is designed to target specific disease-associated microRNAs that are implicated in the pathogenesis of DMD. By modulating the levels or activity of these miRNAs, CUR102 aims to regulate gene expression pathways involved in muscle degeneration and regeneration, potentially offering a novel approach to slowing disease progression in patients with DMD. As part of Curamys's broader miRNA platform, CUR102 represents a targeted approach to addressing the underlying molecular drivers of muscular dystrophy.
Beyond the preview
Go deeper on CUR102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CUR102.